HB 2154 Summary

• Creates "Katie and Cayman's Law" to establish statewide investigational new drug applications for clinical trials using cannabidiol to treat severe forms of epilepsy in patients 18 years old or younger.

• Authorizes licensed physicians in Oklahoma to serve as principal investigators for these clinical trials if approved by the FDA, registered with the Drug Enforcement Administration, and registered with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control.

• Permits the use of FDA-approved cannabidiol (with no more than 0.3% tetrahydrocannabinol) from approved sources for treatment of Lennox-Gastaut Syndrome, Dravet Syndrome, or other severe refractory epilepsy not adequately treated by traditional therapies.

• Provides legal protection against arrest, prosecution, or penalties for persons acting in compliance with the clinical trial provisions.

• Requires clinical trials to conclude by December 31, 2017, with continuation only by legislative concurrent resolution; mandates the State Commissioner of Health submit a report to specified committees with findings and data from the trials.